Cite
HARVARD Citation
Jelinek, T. et al. (2020). Venetoclax plus bortezomib and dexamethasone in heavily pretreated end‐stage myeloma patients without t(11;14): A real‐world cohort. Hematological oncology. 38 (3), pp. 412-414. [Online].
This is an interim version of our Electronic Legal Deposit Catalogue-eJournals and eBooks while we continue to recover from a cyber-attack.
Jelinek, T. et al. (2020). Venetoclax plus bortezomib and dexamethasone in heavily pretreated end‐stage myeloma patients without t(11;14): A real‐world cohort. Hematological oncology. 38 (3), pp. 412-414. [Online].